Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies

  • Technology appraisal guidance
  • TA772
  • Published: 

Tools and resources

Tools and resources to help you put the guidance into practice.

Resource impact

Guidance into practice